These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

128 related articles for article (PubMed ID: 35882670)

  • 1. Prognosis of metastatic bone cancer and myeloma patients and long-term risk of medication-related osteonecrosis of the jaw (MRONJ): some critical points.
    Fusco V; Rossi M; Fasciolo A; Gambino A; Palmeri S
    Support Care Cancer; 2022 Dec; 30(12):9707-9709. PubMed ID: 35882670
    [No Abstract]   [Full Text] [Related]  

  • 2. Response to: Prognosis of metastatic bone cancer and myeloma patients and long‑term risk of medication‑related osteonecrosis of the jaw (MRONJ): some critical points.
    Hata H; Imamachi K; Ueda M; Matsuzaka M; Hiraga H; Osanai T; Harabayashi T; Fujimoto K; Oizumi S; Takahashi M; Yoshikawa K; Sato J; Yamazaki Y; Kitagawa Y
    Support Care Cancer; 2022 Dec; 30(12):9693-9695. PubMed ID: 36318340
    [No Abstract]   [Full Text] [Related]  

  • 3. Multiple myeloma and chemical maxillary osteonecrosis. Can both occur simultaneously?
    Junquera S; Álvarez-Yagüe E; Junquera L; Ugalde R; Rúa L
    J Stomatol Oral Maxillofac Surg; 2020 Nov; 121(5):523-526. PubMed ID: 31863926
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Prognosis by cancer type and incidence of zoledronic acid-related osteonecrosis of the jaw: a single-center retrospective study.
    Hata H; Imamachi K; Ueda M; Matsuzaka M; Hiraga H; Osanai T; Harabayashi T; Fujimoto K; Oizumi S; Takahashi M; Yoshikawa K; Sato J; Yamazaki Y; Kitagawa Y
    Support Care Cancer; 2022 May; 30(5):4505-4514. PubMed ID: 35113225
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Cumulative incidence and risk factors for medication-related osteonecrosis of the jaw during long-term prostate cancer management.
    Tani M; Hatano K; Yoshimura A; Horibe Y; Liu Y; Sassi N; Oka T; Okuda Y; Yamamoto A; Uemura T; Yamamichi G; Ishizuya Y; Yamamoto Y; Kato T; Kawashima A; Nonomura N
    Sci Rep; 2024 Jun; 14(1):13451. PubMed ID: 38862617
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Osteonecrosis of the Jaw in Patients Receiving Bone-Targeted Therapies: An Overview--Part I.
    Turner B; Drudge-Coates L; Ali S; Pati J; Nargund V; Ali E; Cheng L; Wells P
    Urol Nurs; 2016; 36(3):111-6, 154. PubMed ID: 27501591
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Prognosis of medication-related osteonecrosis of the jaws in cancer patients using antiresorptive agent zoledronic acid.
    Wei LY; Kok SH; Lee YC; Chiu WY; Wang JJ; Cheng SJ; Chang HH; Lee JJ
    J Formos Med Assoc; 2021 Aug; 120(8):1572-1580. PubMed ID: 33309430
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Dental pathologies in tumor patients with bone metastases or multiple myeloma scheduled for antiresorptive therapy.
    Laimer J; Hechenberger M; Müller D; Walch B; Kolk A; Schnabl D; Schomaker M; Bruckmoser E
    Future Oncol; 2021 Jul; 17(21):2705-2711. PubMed ID: 33880956
    [No Abstract]   [Full Text] [Related]  

  • 9. Radiographic bone loss and the risk of medication-related osteonecrosis of the jaw (MRONJ) in multiple myeloma patients-A retrospective case control study.
    Wazzan T; Kashtwari D; Almaden WF; Gong Y; Chen Y; Moreb J; Katz J
    Spec Care Dentist; 2018 Nov; 38(6):356-361. PubMed ID: 30194738
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A multicenter observational study on Medication-Related Osteonecrosis of the Jaw (MRONJ) in advanced cancer and myeloma patients of a cancer network in North-Western Italy.
    Fusco V; Cabras M; Erovigni F; Dell'Acqua A; Arduino PG; Pentenero M; Appendino P; Basano L; Ferrera FD; Fasciolo A; Caka M; Migliario M
    Med Oral Patol Oral Cir Bucal; 2021 Jul; 26(4):e466-e473. PubMed ID: 33340073
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Associated characteristics and treatment outcomes of medication-related osteonecrosis of the jaw in patients receiving denosumab or zoledronic acid for bone metastases.
    Ikesue H; Mouri M; Tomita H; Hirabatake M; Ikemura M; Muroi N; Yamamoto S; Takenobu T; Tomii K; Kawakita M; Katoh H; Ishikawa T; Yasui H; Hashida T
    Support Care Cancer; 2021 Aug; 29(8):4763-4772. PubMed ID: 33527228
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Risk evaluation of denosumab and zoledronic acid for medication-related osteonecrosis of the jaw in patients with bone metastases: a propensity score-matched analysis.
    Ikesue H; Doi K; Morimoto M; Hirabatake M; Muroi N; Yamamoto S; Takenobu T; Hashida T
    Support Care Cancer; 2022 Mar; 30(3):2341-2348. PubMed ID: 34738163
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Osteonecrosis of the jaw and renal safety in patients with newly diagnosed multiple myeloma: Medical Research Council Myeloma IX Study results.
    Jackson GH; Morgan GJ; Davies FE; Wu P; Gregory WM; Bell SE; Szubert AJ; Navarro Coy N; Drayson MT; Owen RG; Feyler S; Ashcroft AJ; Ross FM; Byrne J; Roddie H; Rudin C; Boyd KD; Osborne WL; Cook G; Child JA
    Br J Haematol; 2014 Jul; 166(1):109-17. PubMed ID: 24673708
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Medication-related osteonecrosis of the jaw in a patient with multiple myeloma: an unusual case with tumor in the surgical specimen.
    Ogawa R; Minami Y; Ono J; Kanri Y; Kobayashi E; Tanaka A; Okada Y; Ogura I
    Oral Radiol; 2022 Apr; 38(2):288-291. PubMed ID: 34387843
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Medication-related osteonecrosis of the jaw: An update on the memorial sloan kettering cancer center experience and the role of premedication dental evaluation in prevention.
    Owosho AA; Liang STY; Sax AZ; Wu K; Yom SK; Huryn JM; Estilo CL
    Oral Surg Oral Med Oral Pathol Oral Radiol; 2018 May; 125(5):440-445. PubMed ID: 29580668
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Is the prevalence of the medication-related osteonecrosis of the jaws underestimated, evaluation in oncological and non-oncological disease.
    Galis B; Zajko J; Hirjak D; Vanko L; Kupcova I; Jurkemik J; Gengelova P; Mikuskova K; Halmova K; Riznic M; Czako L
    Bratisl Lek Listy; 2017; 118(12):724-731. PubMed ID: 29322803
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Switching from zoledronic acid to denosumab increases the risk for developing medication-related osteonecrosis of the jaw in patients with bone metastases.
    Ikesue H; Doi K; Morimoto M; Hirabatake M; Muroi N; Yamamoto S; Takenobu T; Hashida T
    Cancer Chemother Pharmacol; 2021 Jun; 87(6):871-877. PubMed ID: 33791853
    [TBL] [Abstract][Full Text] [Related]  

  • 18. One changing and challenging scenario: the treatment of cancer patients with bone metastases by bisphosphonates and denosumab, the cost-benefit evaluation of different options, and the risk of medication-related osteonecrosis of the jaw (MRONJ).
    Fusco V; Campisi G; Bedogni A
    Support Care Cancer; 2022 Sep; 30(9):7047-7051. PubMed ID: 35312858
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Medication related osteonecrosis of the jaws (MRONJ): Factors related to recurrence after treatment with surgery and platelet rich plasma (PRP) placement.
    Sánchez-Gallego Albertos C; Del Castillo Pardo de Vera JL; Viejo Llorente A; Cebrián Carretero JL
    Med Oral Patol Oral Cir Bucal; 2021 Nov; 26(6):e684-690. PubMed ID: 34704981
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Does regular zoledronic acid change the bone turnover of the jaw in men with metastatic prostate cancer: a possible clue to the pathogenesis of bisphosphonate related osteonecrosis of the jaw?
    Ristow O; Gerngroß C; Schwaiger M; Hohlweg-Majert B; Ristow M; Koerdt S; Schuster R; Otto S; Pautke C
    J Cancer Res Clin Oncol; 2014 Mar; 140(3):487-93. PubMed ID: 24469255
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.